AU2015240519B2 - Substituted spirocyclic inhibitors of autotaxin - Google Patents
Substituted spirocyclic inhibitors of autotaxin Download PDFInfo
- Publication number
- AU2015240519B2 AU2015240519B2 AU2015240519A AU2015240519A AU2015240519B2 AU 2015240519 B2 AU2015240519 B2 AU 2015240519B2 AU 2015240519 A AU2015240519 A AU 2015240519A AU 2015240519 A AU2015240519 A AU 2015240519A AU 2015240519 B2 AU2015240519 B2 AU 2015240519B2
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- decan
- fluoro
- triazaspiro
- dioxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 C[C@@](*)(C(N(C*CC1)NCC11N(*)*N(*)C1=O)=C)NC(*)=O Chemical compound C[C@@](*)(C(N(C*CC1)NCC11N(*)*N(*)C1=O)=C)NC(*)=O 0.000 description 32
- OIAOLAZZXWVGSF-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1(C#N)Nc1ccccc1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1(C#N)Nc1ccccc1)=O OIAOLAZZXWVGSF-UHFFFAOYSA-N 0.000 description 1
- SUJOJJFVULOWHX-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1(C(N(C)C1)=O)N1c(cc1)ccc1-c1n[nH]cn1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1(C(N(C)C1)=O)N1c(cc1)ccc1-c1n[nH]cn1)=O SUJOJJFVULOWHX-UHFFFAOYSA-N 0.000 description 1
- GPNGSTGBUDAMNV-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1(C(N(C)C1=O)=O)N1c(cc1)ccc1C(O)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1(C(N(C)C1=O)=O)N1c(cc1)ccc1C(O)=O)=O GPNGSTGBUDAMNV-UHFFFAOYSA-N 0.000 description 1
- HZSCZTPGFGYGKY-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1(C(N(C)C1=O)=O)N1c1cc(C)c(C)cc1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1(C(N(C)C1=O)=O)N1c1cc(C)c(C)cc1)=O HZSCZTPGFGYGKY-UHFFFAOYSA-N 0.000 description 1
- BGSXYEGDZXPJEE-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1(C(N(CCBr)C1)=O)N1c(cc1)ccc1C(OC)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1(C(N(CCBr)C1)=O)N1c(cc1)ccc1C(OC)=O)=O BGSXYEGDZXPJEE-UHFFFAOYSA-N 0.000 description 1
- WFYWNZAFKBBGCF-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1(C(N1C)=O)NC1=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1(C(N1C)=O)NC1=O)=O WFYWNZAFKBBGCF-UHFFFAOYSA-N 0.000 description 1
- CUJBBWOMLPKQNR-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1(C(NC1=O)=O)N1c(cc1)cc(O2)c1N(C)C2=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1(C(NC1=O)=O)N1c(cc1)cc(O2)c1N(C)C2=O)=O CUJBBWOMLPKQNR-UHFFFAOYSA-N 0.000 description 1
- LQKJPBCCNFJUCX-ZCFIWIBFSA-N CC(C)[C@H](C(C)=O)N Chemical compound CC(C)[C@H](C(C)=O)N LQKJPBCCNFJUCX-ZCFIWIBFSA-N 0.000 description 1
- DOWUROLBYSJDHJ-CYBMUJFWSA-N CC(C)[C@H](C(C)=O)NC(c(cc(C)cc1)c1F)=O Chemical compound CC(C)[C@H](C(C)=O)NC(c(cc(C)cc1)c1F)=O DOWUROLBYSJDHJ-CYBMUJFWSA-N 0.000 description 1
- XPEFIYKQGYTMGA-RXMQYKEDSA-N CC(C)[C@H](C(I)=O)NC Chemical compound CC(C)[C@H](C(I)=O)NC XPEFIYKQGYTMGA-RXMQYKEDSA-N 0.000 description 1
- IWOYLNGDRQQVEI-HSZRJFAPSA-N CC(C)[C@H](C(N(CC1)CCC1(C(N(C)C1=O)=O)N1c1ccc(C)cc1)=O)NC(c1cc(C)ccc1F)=O Chemical compound CC(C)[C@H](C(N(CC1)CCC1(C(N(C)C1=O)=O)N1c1ccc(C)cc1)=O)NC(c1cc(C)ccc1F)=O IWOYLNGDRQQVEI-HSZRJFAPSA-N 0.000 description 1
- UWIKYILXQMHXMZ-QMGKSUCJSA-N CC(C)[C@H](C(N(CC1)CCC1(C(N1C)=O)N(/C(/C=C)=C/I)C1=C)O)N Chemical compound CC(C)[C@H](C(N(CC1)CCC1(C(N1C)=O)N(/C(/C=C)=C/I)C1=C)O)N UWIKYILXQMHXMZ-QMGKSUCJSA-N 0.000 description 1
- PBEYUBCMPVBLEB-GHCUNRQQSA-N CC(C)[C@H](C(N(CC1)CCC1(C(N1C)=O)N(C/C=C(/C=NN2C)\C2=C/C)C1=O)=O)NC(c(cc(C(F)(F)F)cc1)c1F)=O Chemical compound CC(C)[C@H](C(N(CC1)CCC1(C(N1C)=O)N(C/C=C(/C=NN2C)\C2=C/C)C1=O)=O)NC(c(cc(C(F)(F)F)cc1)c1F)=O PBEYUBCMPVBLEB-GHCUNRQQSA-N 0.000 description 1
- QULFZEQSRXXWTM-YABDQXBESA-N CC(C)[C@H](C(N(CC1)CCC1(C(N1C)=O)N(CC(C2)CC2OC)C1=O)=O)NC(C1=CCC(C)=CC=C1F)=O Chemical compound CC(C)[C@H](C(N(CC1)CCC1(C(N1C)=O)N(CC(C2)CC2OC)C1=O)=O)NC(C1=CCC(C)=CC=C1F)=O QULFZEQSRXXWTM-YABDQXBESA-N 0.000 description 1
- FDAWOYJCBVRUDO-QYGXFBIXSA-N CC(C)[C@H](C(N(CC1)CCC1(C(N1C)=O)N(CC(C2)CC2OC)C1=O)=O)NC(c1cc(C(F)(F)F)ccc1F)=O Chemical compound CC(C)[C@H](C(N(CC1)CCC1(C(N1C)=O)N(CC(C2)CC2OC)C1=O)=O)NC(c1cc(C(F)(F)F)ccc1F)=O FDAWOYJCBVRUDO-QYGXFBIXSA-N 0.000 description 1
- OQINAIGBARSKIL-OAQYLSRUSA-N CC(C)[C@H](C(N(CC1)CCC1(C(N1C)=O)N(c(cc2)cc3c2[nH]nc3)[IH]1=O)=O)NC(c1ncccc1)=O Chemical compound CC(C)[C@H](C(N(CC1)CCC1(C(N1C)=O)N(c(cc2)cc3c2[nH]nc3)[IH]1=O)=O)NC(c1ncccc1)=O OQINAIGBARSKIL-OAQYLSRUSA-N 0.000 description 1
- ACGXGWGLIIYBKW-UHFFFAOYSA-N CC(C1C=CC=C(C)C1F)=O Chemical compound CC(C1C=CC=C(C)C1F)=O ACGXGWGLIIYBKW-UHFFFAOYSA-N 0.000 description 1
- PZWSMLUJDFFGLS-JAIQZWGSSA-N CC(N(C(CC1)(C[IH]N1C(OC(C)(C)C)=O)C(N1C)=O)[IH]1=O)O/C=N\C(C)=C Chemical compound CC(N(C(CC1)(C[IH]N1C(OC(C)(C)C)=O)C(N1C)=O)[IH]1=O)O/C=N\C(C)=C PZWSMLUJDFFGLS-JAIQZWGSSA-N 0.000 description 1
- CYNFEPKQDJHIMV-UHFFFAOYSA-N CC(c(cc(cc1)Cl)c1Cl)=O Chemical compound CC(c(cc(cc1)Cl)c1Cl)=O CYNFEPKQDJHIMV-UHFFFAOYSA-N 0.000 description 1
- WBPAOUHWPONFEQ-UHFFFAOYSA-N CC(c(cc1Cl)ccc1Cl)=O Chemical compound CC(c(cc1Cl)ccc1Cl)=O WBPAOUHWPONFEQ-UHFFFAOYSA-N 0.000 description 1
- PCRBDWBHZOEBBF-NBXNUCLWSA-N CCc(cc1C(N[C@H](C(C)OC)C(N(CC2)CCC2(C(N(C)CC2=O)=O)N2c2ccc(C)cc2)=O)=O)ccc1F Chemical compound CCc(cc1C(N[C@H](C(C)OC)C(N(CC2)CCC2(C(N(C)CC2=O)=O)N2c2ccc(C)cc2)=O)=O)ccc1F PCRBDWBHZOEBBF-NBXNUCLWSA-N 0.000 description 1
- CAMLYXXGGGUBTP-FDDCHVKYSA-N CCc(cc1C(N[C@H]([C@H](C)OC)C(N(CC2)CCC2(C(N(C)C2=O)=O)N2c2ccccc2)=O)=O)ccc1F Chemical compound CCc(cc1C(N[C@H]([C@H](C)OC)C(N(CC2)CCC2(C(N(C)C2=O)=O)N2c2ccccc2)=O)=O)ccc1F CAMLYXXGGGUBTP-FDDCHVKYSA-N 0.000 description 1
- DPGGPRJRBHDFAF-UHFFFAOYSA-N CN(C(C1(CCNCC1)N1c(cc2)cc3c2[nH]nc3)=O)C1=O Chemical compound CN(C(C1(CCNCC1)N1c(cc2)cc3c2[nH]nc3)=O)C1=O DPGGPRJRBHDFAF-UHFFFAOYSA-N 0.000 description 1
- HPNDERZNSPSOTB-UHFFFAOYSA-N CN(C(C1(CCNCC1)N1c(cc2)ccc2-c2n[nH]nn2)=O)C1=O Chemical compound CN(C(C1(CCNCC1)N1c(cc2)ccc2-c2n[nH]nn2)=O)C1=O HPNDERZNSPSOTB-UHFFFAOYSA-N 0.000 description 1
- QRRNZWVFXNEBAJ-UHFFFAOYSA-N CN(C(C1(CCNCC1)N1c2ccncc2)=O)C1=O Chemical compound CN(C(C1(CCNCC1)N1c2ccncc2)=O)C1=O QRRNZWVFXNEBAJ-UHFFFAOYSA-N 0.000 description 1
- GZSXHVISWUQELG-PKOBYXMFSA-N C[C@@H]([C@H](C(N(CC1)CCC1(C(N(C)C1)=O)N1c1ccccc1)=O)NC(OC(C)(C)C)=O)OC Chemical compound C[C@@H]([C@H](C(N(CC1)CCC1(C(N(C)C1)=O)N1c1ccccc1)=O)NC(OC(C)(C)C)=O)OC GZSXHVISWUQELG-PKOBYXMFSA-N 0.000 description 1
- ALRDYLPFCGJGMC-UHFFFAOYSA-N Cc(c(C)c1)ccc1N(C1(CCNCC1)C(N1C)=O)C1=O Chemical compound Cc(c(C)c1)ccc1N(C1(CCNCC1)C(N1C)=O)C1=O ALRDYLPFCGJGMC-UHFFFAOYSA-N 0.000 description 1
- TYNBCXXIJBHILP-UHFFFAOYSA-N Cc(cc1)ccc1N(CN1C)C2(CC[IH]CC2)C1=O Chemical compound Cc(cc1)ccc1N(CN1C)C2(CC[IH]CC2)C1=O TYNBCXXIJBHILP-UHFFFAOYSA-N 0.000 description 1
- NIAZWWDQIHAOJT-UHFFFAOYSA-N OC(CNC(c1cc(C(F)(F)F)ccc1F)=O)=O Chemical compound OC(CNC(c1cc(C(F)(F)F)ccc1F)=O)=O NIAZWWDQIHAOJT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019264641A AU2019264641A1 (en) | 2014-04-04 | 2019-11-15 | Substituted spirocyclic inhibitors of autotaxin |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461975123P | 2014-04-04 | 2014-04-04 | |
| US61/975,123 | 2014-04-04 | ||
| PCT/US2015/024338 WO2015154023A1 (en) | 2014-04-04 | 2015-04-03 | Substituted spirocydic inhibitors of autotaxin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019264641A Division AU2019264641A1 (en) | 2014-04-04 | 2019-11-15 | Substituted spirocyclic inhibitors of autotaxin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015240519A1 AU2015240519A1 (en) | 2016-10-20 |
| AU2015240519B2 true AU2015240519B2 (en) | 2019-08-15 |
Family
ID=54241341
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015240519A Ceased AU2015240519B2 (en) | 2014-04-04 | 2015-04-03 | Substituted spirocyclic inhibitors of autotaxin |
| AU2019264641A Abandoned AU2019264641A1 (en) | 2014-04-04 | 2019-11-15 | Substituted spirocyclic inhibitors of autotaxin |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019264641A Abandoned AU2019264641A1 (en) | 2014-04-04 | 2019-11-15 | Substituted spirocyclic inhibitors of autotaxin |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10011601B2 (enExample) |
| EP (1) | EP3125895A4 (enExample) |
| JP (2) | JP6616821B2 (enExample) |
| KR (1) | KR20160133004A (enExample) |
| CN (1) | CN107106559A (enExample) |
| AP (1) | AP2016009496A0 (enExample) |
| AU (2) | AU2015240519B2 (enExample) |
| CA (1) | CA2943874A1 (enExample) |
| CL (1) | CL2016002516A1 (enExample) |
| CR (1) | CR20160496A (enExample) |
| CU (1) | CU24442B1 (enExample) |
| DO (1) | DOP2016000270A (enExample) |
| EA (1) | EA201691840A1 (enExample) |
| EC (1) | ECSP16084293A (enExample) |
| IL (1) | IL248050A0 (enExample) |
| MD (1) | MD20160116A2 (enExample) |
| MX (1) | MX2016013049A (enExample) |
| PE (1) | PE20170206A1 (enExample) |
| PH (1) | PH12016501922A1 (enExample) |
| SG (1) | SG11201607920RA (enExample) |
| WO (1) | WO2015154023A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI633087B (zh) | 2012-06-13 | 2018-08-21 | 赫孚孟拉羅股份公司 | 新穎二氮雜螺環烷及氮雜螺環烷 |
| EP3590940B1 (en) | 2012-09-25 | 2021-06-09 | F. Hoffmann-La Roche AG | Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| NO3074400T3 (enExample) | 2013-11-26 | 2018-04-14 | ||
| MA39792B1 (fr) | 2014-03-26 | 2019-12-31 | Hoffmann La Roche | Composés bicycliques en tant qu'inhibiteurs de production d'autotaxine (atx) et d'acide lysophosphatidique (lpa) |
| EP3122751B1 (en) | 2014-03-26 | 2019-10-30 | F.Hoffmann-La Roche Ag | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| CR20160496A (es) | 2014-04-04 | 2017-01-02 | X-Rx Inc | Inhibidores espirocíclicos sustituidos de la autotaxina |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| MX387736B (es) | 2015-09-04 | 2025-03-18 | Hoffmann La Roche | Derivados de fenoximetilo. |
| MX2017015034A (es) | 2015-09-24 | 2018-04-13 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca). |
| KR20180054634A (ko) | 2015-09-24 | 2018-05-24 | 에프. 호프만-라 로슈 아게 | 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 신규한 이환형 화합물 |
| PE20180451A1 (es) | 2015-09-24 | 2018-03-05 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores de atx |
| CN107635995B (zh) | 2015-09-24 | 2022-08-19 | 豪夫迈·罗氏有限公司 | 作为atx抑制剂的二环化合物 |
| AU2017228371A1 (en) | 2016-03-04 | 2018-09-13 | Gilead Sciences, Inc. | Compositions and combinations of autotaxin inhibitors |
| JOP20190107A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| CN108456208B (zh) * | 2017-02-22 | 2021-04-16 | 广州市恒诺康医药科技有限公司 | 氮杂螺环类化合物及其制备方法和应用 |
| CN110382484B (zh) | 2017-03-16 | 2022-12-06 | 豪夫迈·罗氏有限公司 | 新的作为atx抑制剂的二环化合物 |
| MA49879A (fr) | 2017-03-16 | 2020-06-24 | Hoffmann La Roche | Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca |
| US10961242B2 (en) | 2017-05-17 | 2021-03-30 | Legochem Biosciences, Inc. | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same |
| KR101798840B1 (ko) | 2017-05-17 | 2017-11-17 | 주식회사 레고켐 바이오사이언스 | 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물 |
| JP7189143B2 (ja) | 2017-09-29 | 2022-12-13 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2020051230A1 (en) * | 2018-09-04 | 2020-03-12 | X-Rx, Inc. | Amorphous pharmaceutical compositions and uses thereof |
| WO2022006470A1 (en) | 2020-07-01 | 2022-01-06 | Vanderbilt University | Methods of treatment for a kidney disease |
| CN116157404B (zh) * | 2020-08-14 | 2025-10-14 | 诺华股份有限公司 | 杂芳基取代的螺哌啶基衍生物及其药物用途 |
| TWI904281B (zh) | 2020-11-13 | 2025-11-11 | 丹麥商Ｈ 朗德貝克公司 | Magl抑制劑 |
| CN112675308B (zh) * | 2020-12-09 | 2023-05-05 | 中国人民解放军军事科学院军事医学研究院 | 抑制enpp2基因和/或蛋白表达的物质在制备治疗多发性骨髓瘤的药物中的应用 |
| PT4274572T (pt) * | 2021-01-05 | 2026-03-11 | Zydus Lifesciences Ltd | Novos inibidores da autotaxina |
| IL316302A (en) | 2022-05-04 | 2024-12-01 | H Lundbeck As | Crystalline form of 111333-hexafluoropro s-1-pyridazin-3-ylca azaspiro2.5octane-6- as a monoacylglycerol lipase inhibitor |
| CN119998288A (zh) * | 2022-09-30 | 2025-05-13 | 基因泰克公司 | 胆固醇生物合成的乙内酰脲调节剂及其用于促进髓鞘再生的用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002070511A1 (en) * | 2001-03-02 | 2002-09-12 | Bristol-Myers Squibb Company | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| WO2002069905A2 (en) * | 2001-03-02 | 2002-09-12 | Bristol-Myers Squibb Company | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
| WO2010037081A1 (en) * | 2008-09-29 | 2010-04-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific spiro-piperidine compounds |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5877182A (en) | 1996-09-13 | 1999-03-02 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
| EP0991753A4 (en) | 1997-05-08 | 2001-07-11 | Smithkline Beecham Corp | PROTEAS INHIBITORS |
| GB0030303D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| IL160990A0 (en) * | 2001-10-01 | 2004-08-31 | Bristol Myers Squibb Co | Spiro-hydantoin compounds useful as anti-inflammatory agents |
| US20040192674A1 (en) | 2003-02-14 | 2004-09-30 | Marquis Robert W. | Cathepsin L inhibitors |
| EP1599447A1 (en) | 2003-02-28 | 2005-11-30 | Galderma Research & Development, S.N.C. | Ligands that modulate lxr-type receptors |
| US7576175B2 (en) * | 2004-05-27 | 2009-08-18 | The Regents Of The University Of California | Alpha-4 beta-1 integrin ligands for imaging and therapy |
| JPWO2006137465A1 (ja) | 2005-06-24 | 2009-01-22 | 塩野義製薬株式会社 | 含窒素複素環誘導体 |
| US7601844B2 (en) | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8906859B2 (en) * | 2006-11-10 | 2014-12-09 | Cera Therapeutics, Inc. | Uses of kappa opioid synthetic peptide amides |
| CN101534824A (zh) * | 2006-11-17 | 2009-09-16 | 艾博特公司 | 作为化学活素受体拮抗剂的氨基吡咯烷 |
| US8378100B2 (en) | 2008-01-09 | 2013-02-19 | University Of Virginia Patent Foundation | Phosphonate derivatives as autotaxin inhibitors |
| KR20100134680A (ko) | 2008-03-20 | 2010-12-23 | 포레스트 래보러토리즈 홀딩스 리미티드 | 스테아로일-ｃｏａ 불포화효소의 저해물질로서 신규한 피페리딘 유도체 |
| WO2009151644A2 (en) | 2008-06-13 | 2009-12-17 | Yale University | Small molecule inhibitors of autotaxin methods of use |
| EA201100879A1 (ru) | 2008-12-01 | 2012-01-30 | Мерк Патент Гмбх | Производные пиридопиримидина в качестве ингибиторов аутотаксина |
| JP5767205B2 (ja) | 2009-04-02 | 2015-08-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | オートタキシン阻害剤としての複素環式化合物 |
| CA2757415C (en) | 2009-04-02 | 2018-02-06 | Merck Patent Gmbh | Autotaxin inhibitors |
| EP2623101B1 (en) | 2009-04-02 | 2021-04-21 | Merck Patent GmbH | Piperidine and piperazine derivatives as autotaxin inhibitors |
| EA020031B1 (ru) * | 2009-06-11 | 2014-08-29 | Эббви Бахамаз Лтд. | Противовирусные соединения |
| DE102009033392A1 (de) | 2009-07-16 | 2011-01-20 | Merck Patent Gmbh | Heterocyclische Verbindungen als Autotaxin-Inhibitoren II |
| CN102574822A (zh) | 2009-08-04 | 2012-07-11 | 阿米拉制药公司 | 作为溶血磷脂酸受体拮抗剂的化合物 |
| KR101184115B1 (ko) * | 2009-08-31 | 2012-09-18 | 일동제약주식회사 | 신규 펩티드 데포르밀라제 저해제 화합물 및 그 제조방법 |
| US8497371B2 (en) | 2009-10-26 | 2013-07-30 | University Of Memphis Research Foundation | Pipemidic acid derivative autotaxin inhibitors |
| US8518945B2 (en) | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| WO2011116867A1 (de) | 2010-03-26 | 2011-09-29 | Merck Patent Gmbh | Benzonaphthyridinamine als autotaxin-inhibitoren |
| JP2011219368A (ja) | 2010-04-02 | 2011-11-04 | Daiichi Sankyo Co Ltd | Ｎ−サリチルアミノ酸誘導体 |
| ES2646834T3 (es) | 2010-08-20 | 2017-12-18 | Amira Pharmaceuticals, Inc. | Inhibidores de autotaxina y usos de los mismos |
| US9260416B2 (en) | 2011-05-27 | 2016-02-16 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
| AR086554A1 (es) * | 2011-05-27 | 2014-01-08 | Novartis Ag | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
| ES2748656T3 (es) | 2011-10-28 | 2020-03-17 | Inhibitaxin Ltd | Derivados de piridazina útiles en terapia |
| TWI633087B (zh) | 2012-06-13 | 2018-08-21 | 赫孚孟拉羅股份公司 | 新穎二氮雜螺環烷及氮雜螺環烷 |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| TW201500356A (zh) | 2013-04-12 | 2015-01-01 | Lilly Co Eli | 二氫吡啶并嘧啶化合物 |
| EP3022201A1 (en) | 2013-07-18 | 2016-05-25 | Novartis AG | Autotaxin inhibitors |
| PT3022202T (pt) | 2013-07-18 | 2019-09-03 | Novartis Ag | Inibidores da autotaxina compreendendo um núcleo beteroaromático anel-benzilo-amida-ciclo |
| US9951026B2 (en) | 2013-09-17 | 2018-04-24 | Pharmakea, Inc. | Heterocyclic vinyl autotaxin inhibitor compounds |
| US9714240B2 (en) | 2013-09-17 | 2017-07-25 | Pharmakea, Inc. | Vinyl autotaxin inhibitor compounds |
| EP3049405A4 (en) | 2013-09-26 | 2017-03-08 | Pharmakea Inc. | Autotaxin inhibitor compounds |
| CR20160496A (es) | 2014-04-04 | 2017-01-02 | X-Rx Inc | Inhibidores espirocíclicos sustituidos de la autotaxina |
| WO2015175171A1 (en) | 2014-04-23 | 2015-11-19 | X-Rx Discovery, Inc. | Substituted n-(2-(amino)-2-oxoethyl)benzamide inhibitors of autotaxin and their preparation and use in the treatment of lpa-dependent or lpa-mediated diseases |
-
2015
- 2015-04-03 CR CR20160496A patent/CR20160496A/es unknown
- 2015-04-03 US US15/300,762 patent/US10011601B2/en not_active Expired - Fee Related
- 2015-04-03 WO PCT/US2015/024338 patent/WO2015154023A1/en not_active Ceased
- 2015-04-03 JP JP2017503794A patent/JP6616821B2/ja not_active Expired - Fee Related
- 2015-04-03 MX MX2016013049A patent/MX2016013049A/es unknown
- 2015-04-03 CU CU2016000150A patent/CU24442B1/es unknown
- 2015-04-03 AU AU2015240519A patent/AU2015240519B2/en not_active Ceased
- 2015-04-03 PE PE2016001885A patent/PE20170206A1/es unknown
- 2015-04-03 SG SG11201607920RA patent/SG11201607920RA/en unknown
- 2015-04-03 MD MDA20160116A patent/MD20160116A2/ro not_active Application Discontinuation
- 2015-04-03 CA CA2943874A patent/CA2943874A1/en not_active Abandoned
- 2015-04-03 KR KR1020167030589A patent/KR20160133004A/ko not_active Withdrawn
- 2015-04-03 AP AP2016009496A patent/AP2016009496A0/en unknown
- 2015-04-03 CN CN201580028170.3A patent/CN107106559A/zh active Pending
- 2015-04-03 EA EA201691840A patent/EA201691840A1/ru unknown
- 2015-04-03 EP EP15773254.6A patent/EP3125895A4/en not_active Withdrawn
-
2016
- 2016-09-26 IL IL248050A patent/IL248050A0/en unknown
- 2016-09-28 PH PH12016501922A patent/PH12016501922A1/en unknown
- 2016-10-03 DO DO2016000270A patent/DOP2016000270A/es unknown
- 2016-10-04 CL CL2016002516A patent/CL2016002516A1/es unknown
- 2016-10-26 EC ECIEPI201684293A patent/ECSP16084293A/es unknown
-
2018
- 2018-02-14 US US15/896,905 patent/US10233182B2/en not_active Expired - Fee Related
-
2019
- 2019-04-12 US US16/256,429 patent/US20190225611A1/en not_active Abandoned
- 2019-11-08 JP JP2019203023A patent/JP2020040960A/ja active Pending
- 2019-11-15 AU AU2019264641A patent/AU2019264641A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002070511A1 (en) * | 2001-03-02 | 2002-09-12 | Bristol-Myers Squibb Company | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| WO2002069905A2 (en) * | 2001-03-02 | 2002-09-12 | Bristol-Myers Squibb Company | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
| WO2010037081A1 (en) * | 2008-09-29 | 2010-04-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific spiro-piperidine compounds |
Non-Patent Citations (1)
| Title |
|---|
| REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (2000-11-15), URL: STN * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6616821B2 (ja) | 2019-12-04 |
| IL248050A0 (en) | 2016-11-30 |
| US20180282332A1 (en) | 2018-10-04 |
| MD20160116A2 (ro) | 2017-04-30 |
| US20190225611A1 (en) | 2019-07-25 |
| ECSP16084293A (es) | 2017-01-31 |
| AU2015240519A1 (en) | 2016-10-20 |
| AP2016009496A0 (en) | 2016-10-31 |
| SG11201607920RA (en) | 2016-10-28 |
| KR20160133004A (ko) | 2016-11-21 |
| CA2943874A1 (en) | 2015-10-08 |
| US10233182B2 (en) | 2019-03-19 |
| AU2019264641A1 (en) | 2019-12-05 |
| EP3125895A4 (en) | 2017-08-30 |
| CN107106559A (zh) | 2017-08-29 |
| JP2017513932A (ja) | 2017-06-01 |
| CL2016002516A1 (es) | 2017-05-12 |
| EP3125895A1 (en) | 2017-02-08 |
| CR20160496A (es) | 2017-01-02 |
| PE20170206A1 (es) | 2017-04-09 |
| JP2020040960A (ja) | 2020-03-19 |
| DOP2016000270A (es) | 2016-12-15 |
| US10011601B2 (en) | 2018-07-03 |
| EA201691840A1 (ru) | 2017-03-31 |
| US20170166568A1 (en) | 2017-06-15 |
| PH12016501922A1 (en) | 2016-12-19 |
| CU24442B1 (es) | 2019-09-04 |
| WO2015154023A1 (en) | 2015-10-08 |
| CU20160150A7 (es) | 2017-02-02 |
| MX2016013049A (es) | 2017-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10233182B2 (en) | Substituted spirocyclic inhibitors of autotaxin | |
| JP6592008B2 (ja) | オートタキシンの置換ｎ−（２−アミノ）−２−オキソエチルベンズアミド阻害剤およびそれらの調製、ならびにｌｐａ依存性またはｌｐａ媒介性疾患の処置における使用 | |
| AU2017311645B2 (en) | Pyridopyrimdinone CDK2/4/6 inhibitors | |
| JP7112488B2 (ja) | タンパク質キナーゼ阻害剤としての複素環化合物 | |
| JP2011520896A (ja) | キナーゼ阻害剤としてのピロロピリジン | |
| JP2023509495A (ja) | ＲＯＲγｔ阻害剤、その製造方法及び使用 | |
| UA114323C2 (uk) | Інгібітори nampt | |
| WO2020223255A1 (en) | 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2 | |
| TW202122382A (zh) | 乙內醯脲衍生物 | |
| AU2020400010A1 (en) | Heterocyclic compounds as modulators of Stimulator of Interferon Genes (STING) | |
| JP6322275B2 (ja) | ヤヌスキナーゼ阻害剤としてのｎ−（２−シアノヘテロシクリル）ピラゾロピリドン | |
| TW202146384A (zh) | 取代的氮雜五元環類化合物及其在藥物中的應用 | |
| KR102133595B1 (ko) | 단백질 키나제 억제제로서의 헤테로고리 화합물 | |
| WO2019013562A1 (ko) | 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물 | |
| OA18996A (en) | Substituted Spirocyclic Inhibitors of Autotaxin | |
| KR102112336B1 (ko) | 단백질 키나제 억제제로서의 헤테로고리 화합물 | |
| RU2783723C2 (ru) | Гетероциклическое соединение в качестве ингибитора протеинкиназы | |
| JP7061663B2 (ja) | 新規な１ｈ－ピラゾロピリジン誘導体およびこれを含む薬学組成物 | |
| EP4604946A1 (en) | Alkylamine-containing small molecule degraders of bcl6 | |
| NZ787918A (en) | Pyridopyrimdinone CDK2/4/6 inhibitors | |
| EA041386B1 (ru) | Спироциклические соединения и способы их получения и применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |